China Shenghuo Pharmaceutical Holdings, Inc. (nyse alternext us:KUN) ("China Shenghuo" or the "Company"), a China-based pharmaceutical company primarily engaged in the research, development, manufacture, and marketing of Traditional Chinese Medicine (TCM), nutritional supplement and cosmetic products, announced that Mr. Raymond Wang has joined the Company as part-time Chief Financial Officer, effective as of April 20, 2011.
He joins China Shenghuo from China Biwin Consulting Co., Ltd. and Guangzhou Biwin Financial Consulting Co., Ltd. where he was responsible for financial consulting, internal controls, tax and Sarbanes-Oxley Section 404 ("SOX404") compliance.
Mr. Wang began his career at one of Big Four accounting firms where he managed audit engagements, reviewed the working papers, communicated with top management and liaised with internal tax professionals. He later worked at another US accounting firm, where his responsibilities included US GAAP audits, advisory service on the compliance with SOX 404 and pre-audit advisory service, such as enhancing the internal control, preparing financial reports and U.S. GAAP conversion. He holds a Bachelor of Business degree from Guangdong University of Foreign Studies and is a member of the Chinese Institute of Certified Public Accountants (CICPA). He is fluent in English, Mandarin and Cantonese.
The former CFO, Chuanxiang Huang, resigned from his position as Chief Financial Officer of the Company, effective as of April 18, 2011.
About China Shenghuo
Founded in 1995, China Shenghuo is a specialty pharmaceutical company that primarily focuses on the research, development, manufacture and marketing of Sanchi-based medicinal, pharmaceutical, nutritional supplement, and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which is currently being listed in the 2010 Provincial Insurance Catalogue of sixteen provinces and remains to be listed in the 2009 Provincial Insurance Catalogue of three provinces around China. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Singapore, Japan, Malaysia and Thailand and to European countries such as the United Kingdom, Tajikistan, Russia and Kyrgyzstan. For more information, please visit www.shenghuo.com.cn.